Differences in the composite scores for alertness of attention, calmness, and contentment did not reach statistical significance for levomilnacipran ER versus placebo on any factors (data not shown).
← all excerpts
A phase III, double-blind, placebo-controlled, flexible-dose study of levomilnacipran extended-release in patients with major depressive disorder.
1
—
—